Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 9/20 | 0.64 |
| ▸ | CTSS | P25774 | 3/20 | 0.61 |
| ▸ | CTSK | P43235 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | ACE | P12821 | 1/20 | 0.58 |
| ▸ | CTSL | P07711 | 1/20 | 0.54 |
| ▸ | CTSB | P07858 | 1/20 | 0.54 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.52 |
| ▸ | APP | P05067 | 1/20 | 0.52 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.52 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.52 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.52 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.52 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.52 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20825295 | 1.00 | REN (0.64) | RENCTSSCTSKMAPK1ACE | |
| SCHEMBL18257557 | 1.00 | REN (0.64) | RENCTSSCTSKMAPK1ACE | |
| SCHEMBL28728712 | 1.00 | REN (0.64) | RENCTSSCTSKMAPK1ACE | |
| SCHEMBL18257572 | 1.00 | REN (0.64) | RENCTSSCTSKMAPK1ACE | |
| SCHEMBL18257495 | 1.00 | REN (0.64) | RENCTSSCTSKMAPK1ACE | |
| SCHEMBL23616313 | 1.00 | REN (0.64) | RENCTSSCTSKMAPK1ACE | |
| SCHEMBL13743068 | 1.00 | REN (0.64) | RENCTSSCTSKMAPK1ACE | |
| SCHEMBL23734217 | 0.96 | REN (0.64) | RENCTSSCTSKMAPK1ACE | |
| SCHEMBL21367422 | 0.95 | CTSK (0.64) | RENCTSSCTSKMAPK1CTSL | |
| SCHEMBL15635321 | 0.94 | CTSS (0.65) | RENCTSSCTSKMAPK1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3297678-B1 | AN IMPROVED PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS LTD (IN) | 2021-07-07 | — | — | EP | disclosed |
| US-10800809-B2 | Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof | LAURUS LABS LIMITED (IN) | 2020-10-13 | — | — | US | disclosed |
| US-20190284231-A1 | PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS LIMITED (IN) | 2019-09-19 | — | — | US | disclosed |
| US-10364269-B2 | Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof | LAURUS LABS LIMITED (IN) | 2019-07-30 | — | — | US | disclosed |
| US-20190085026-A1 | AN IMPROVED PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | Laurus Labs Ltd. (IN) | 2019-03-21 | — | — | US | disclosed |
| WO-2016185450-A1 | AN IMPROVED PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS PRIVATE LIMITED (IN) | 2016-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190085026-A1 | AN IMPROVED PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | PRCP, SF3B5, GBA1 | REN 22/4885CTSS 139/4885CTSK 201/4885 |
| US-10364269-B2 | Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof | SF3B5, PRCP, GBA1 | REN 17/4885CTSS 132/4885CTSK 252/4885 |
| US-10800809-B2 | Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof | SF3B5, PRCP, GBA1 | REN 17/4885CTSS 132/4885CTSK 252/4885 |
| US-20190284231-A1 | PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | SF3B5, PRCP, GBA1 | REN 17/4885CTSS 132/4885CTSK 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.